Compare Autodesk Inc (ADSK) vs Pfizer Inc (PFE) Price & Performance

Autodesk (ADSK) trades at $249.08, up 2.73% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $6.13B in 2025, with net income reaching $1.11B and a 19.49% net margin. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $2.99 exceeding the $2.84 forecast. Analyst consensus is a Buy with a $305.31 price target, supported by 74.51% of analysts rating it a Buy. Recent news highlights AI investments and strategic acquisitions.

Outlook remains positive given robust earnings growth, high profitability margins, and strategic AI investments. Risks include competitive pressures in software, reliance on economic cycles affecting design software demand, and execution risks from recent acquisitions. The stock offers upside to the consensus target but faces volatility near technical resistance at $253.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.